Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

Coherus Oncology (Nasdaq: CHRS) will release its third quarter 2026 financial results on November 9, 2026.

Rhea-AI Summary

Coherus Oncology (Nasdaq: CHRS) will release its third quarter 2026 financial results on November 9, 2026. Management will host a conference call and webcast at 5:00 p.m. Eastern Daylight Time that day to discuss the results and provide a general business update. Results and related materials will be available on the investor website before the call, with a webcast replay available afterward.

Key Terms

regulation fd, pd-1 inhibitor, phase 1b/2a studies, phase 2 study

4 terms

regulation fd regulatory

"under Regulation FD"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

pd-1 inhibitor medical

"approved next-generation programmed death receptor-1 (“PD-1”) inhibitor"

A PD-1 inhibitor is a type of medicine that helps the immune system recognize and attack cancer cells by blocking the PD-1 checkpoint—a molecular “off switch” that cancer can use to hide from immune defenses. For investors, these drugs matter because they can transform treatment options, drive sales or partnerships, and affect a company’s valuation if clinical trials, approvals, or competitive positioning change; think of them as unlocking a locked door to let the body’s defenses work.

phase 1b/2a studies medical

"currently in Phase 1b/2a studies"

A combined early-stage clinical trial that bridges first-in-human safety work and initial proof-of-concept testing: phase 1b typically expands safety, tolerability and dose-ranging testing into patients (often after initial healthy-volunteer or single-ascending-dose studies), while phase 2a focuses on preliminary evidence of biological activity or clinical effect at selected doses. Together a phase 1b/2a study usually uses dose-escalation and/or dose-expansion cohorts, measures safety, pharmacokinetics and pharmacodynamics, and collects early efficacy or biomarker signals with a relatively small number of patients to inform dose selection and design of larger, later-phase trials. These studies are not designed to provide definitive efficacy or safety conclusions for regulatory approval; rather they guide whether and how to proceed to larger phase 2b or phase 3 trials.

phase 2 study medical

"currently being evaluated in a Phase 2 study"

A phase 2 study is a mid-stage clinical trial that tests whether an experimental drug or treatment actually works for the intended condition and continues to check safety in a larger group of patients than early trials. Think of it as a focused pilot test before a full market launch; positive or negative results strongly affect a drug’s chances of approval, the remaining development time and costs, and therefore an investment’s risk and potential value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at 5:00 p.m. Eastern Daylight Time on November 9, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.

Conference Call Information

When: Monday, November 9, 2026, starting at 5:00 p.m. Eastern Daylight Time.

To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BI55798b5af6004203b3a31cfe6dff187e

Webcast: https://edge.media-server.com/mmc/p/qhta3pue

The press release with the third quarter 2026 financial results and related materials will be available at https://investors.coherus.com before the start of the conference call.

A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.

Please dial in15 minutes early to ensure a timely connection to the call.

Disclosure Information

Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. 

About Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI^® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of its two pipeline candidates in combination with LOQTORZI and through strategic partnerships.

Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and improve outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors; including head and neck squamous cell carcinoma, colorectal cancer, gastric, gastro-esophageal-junction, esophageal adenocarcinoma and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

LOQTORZI^® is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.

Coherus Oncology Contact Information:

For Investors:
Carrie Graham
Vice President, Investor Relations & Advocacy
IR@coherus.com